<DOC>
	<DOCNO>NCT00457795</DOCNO>
	<brief_summary>This study evaluate efficacy safety brimonidine 0.1 % three-times daily patient glaucoma ocular hypertension</brief_summary>
	<brief_title>24-hour IOP-lowering Effect Brimonidine 0.1 %</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>patient openangle glaucoma ocular hypertension allergy brimonidine inability complete 24 hour stay monitoring</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>